Scott Liebman & Team Placed in the Life Sciences and FDA Regulatory group at Sheppard Mullin

Originally published by Whistler Partners Placements on 03.16.22
Scott Liebman Sheppard Group bw
Whistler Partners is pleased to announce the placement of Scott Liebman as co-leader of Sheppard Mullin's Life Sciences and FDA Regulatory industry team. Scott will be joined by four additional members of his team: partner Dominick P. DiSabatino (who will be based in Washington, D.C.), special counsel Eve Costopoulos, associate Alexandra Kitson, and regulatory and compliance specialist Jeremiah Miah (all of whom will be based in New York). Liebman will serve as co-leader of Sheppard Mullin's Life Sciences team, as well as the FDA Regulatory team.

Liebman focuses on complex FDA regulatory, compliance and legal matters affecting global pharmaceutical, biotechnology and medical device manufacturers. He counsels clients on federal and state requirements and develops legal and regulatory strategies to help commercialize their products.

"Adding leading and sophisticated practitioners like Scott, Dom, Eve, Alex and Jeremiah is part of our strategic drive to augment the firm’s life sciences capabilities," said Sheppard Mullin chair Luca Salvi in a statement release by the firm. "This group’s deep understanding of the FDA will be incredibly valuable to our pharmaceutical, biotech, medical device and cosmetics clients. We’re thrilled to add them to our life sciences and FDA regulatory practices."

The placement was led by Josh Bilgrei, Managing Director at Whistler, who said that he is "humbled to make the match between Scott and Sheppard. I've known Scott for decades (we actually went to summer camp together), but since I've known him as an attorney, it's been apparent that he's not only an incredible practitioner, but also a great boss and mentor with a team who would follow him anywhere. When Scott told me he was ready to explore new opportunities, Sheppard Mullin blew us away with their overall firm and life sciences strategy. Shon Glusky, Guy Halgren, Jon Newby and Luca Salvi were all integral to making this deal happen, and it was a pleasure to work with them. I'm looking forward to seeing what Scott and his team accomplish at Sheppard."
To learn more about the move, read Sheppard Mullin's statement HERE.

Topics: IP & Life Sciences Transactions, Josh Bilgrei, Placements, Sheppard Mullin, FDA Regulatory